These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 27256987)

  • 41. Laser-ranibizumab treatment for retinopathy of prematurity in umbral-preumbral disease. Three years of experience.
    Orozco-Gómez LP; Hernández-Salazar L; Moguel-Ancheita S; Ramírez-Moreno MA; Morales-Cruz MV
    Cir Cir; 2011; 79(3):207-214, 225-32. PubMed ID: 22380989
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intravitreal bevacizumab in retinopathy of prematurity: an interventional case series.
    Roohipoor R; Ghasemi H; Ghassemi F; Karkhaneh R; Riazi-Esfahani M; Nili-Ahmadabadi M
    Graefes Arch Clin Exp Ophthalmol; 2011 Sep; 249(9):1295-301. PubMed ID: 21494873
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characteristics of Severe Retinopathy of Prematurity in Infants with Birth Weight above 1500 Grams at a Referral Center in Turkey.
    Gunay M; Celik G; Tuten A; Karatekin G; Bardak H; Ovali F
    PLoS One; 2016; 11(8):e0161692. PubMed ID: 27548628
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Dosing Study of Bevacizumab for Retinopathy of Prematurity: Late Recurrences and Additional Treatments.
    Wallace DK; Dean TW; Hartnett ME; Kong L; Smith LE; Hubbard GB; McGregor ML; Jordan CO; Mantagos IS; Bell EF; Kraker RT;
    Ophthalmology; 2018 Dec; 125(12):1961-1966. PubMed ID: 29887334
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characteristics of retinal vascularization in reactivated retinopathy of prematurity requiring treatment and clinical outcome after reinjection of ranibizumab.
    Jang JH
    Sci Rep; 2024 Jul; 14(1):15647. PubMed ID: 38977744
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intravitreal Bevacizumab for Zone II Retinopathy of Prematurity.
    Larrañaga-Fragoso P; Peralta J; Bravo-Ljubetic L; Pastora N; Abelairas-Gómez J
    J Pediatr Ophthalmol Strabismus; 2016 Nov; 53(6):375-382. PubMed ID: 27537247
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of clinical outcomes of conbercept versus ranibizumab treatment for retinopathy of prematurity: a multicentral prospective randomised controlled trial.
    Wu Z; Zhao J; Lam W; Yang M; Chen L; Huang X; Wei M; Yang H; Lv F; Zhang F; Zeng J; Zhang GM
    Br J Ophthalmol; 2022 Jul; 106(7):975-979. PubMed ID: 33637618
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The clinical study on intravitreous injection of ranibizumab for aggressive posterior retinopathy of prematurity].
    Tian R; Zhang G; Tang S; Guo J; Tan W
    Zhonghua Yan Ke Za Zhi; 2015 Nov; 51(11):822-5. PubMed ID: 26850583
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prospective clinical study of two different treatment regimens of combined laser photocoagulation and intravitreal bevacizumab for retinopathy of prematurity: the Indian Twin Cities ROP Study (ITCROPS) database report number 9.
    Laveti V; Balakrishnan D; Rani PK; Mohamed A; Jalali S
    Int Ophthalmol; 2020 Dec; 40(12):3539-3545. PubMed ID: 32776299
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.
    Mintz-Hittner HA; Kennedy KA; Chuang AZ;
    N Engl J Med; 2011 Feb; 364(7):603-15. PubMed ID: 21323540
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characteristics of 'sawtooth shunt' following anti-vascular endothelial growth factor for aggressive posterior retinopathy of prematurity.
    Padhi TR; Das T; Kaur P; Sutar S; Khalsa A; Modi R; Ali H; Pradhan L; Jalali S
    Int Ophthalmol; 2020 Apr; 40(4):1007-1015. PubMed ID: 31925658
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of a biosimilar ranibizumab monotherapy for the treatment of retinopathy of prematurity.
    Prajapati V; Choudhary T; Chauhan W; Shah S; Handa R; Jahan B; Malviya S; Sengupta S
    Indian J Ophthalmol; 2023 Feb; 71(2):411-415. PubMed ID: 36727329
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nonresponse and Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Treatment.
    Chuluunbat T; Chan RV; Wang NK; Lien R; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
    Ophthalmic Surg Lasers Imaging Retina; 2016 Dec; 47(12):1095-1105. PubMed ID: 27977832
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity.
    Castellanos MA; Schwartz S; García-Aguirre G; Quiroz-Mercado H
    Br J Ophthalmol; 2013 Jul; 97(7):816-9. PubMed ID: 23221964
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Low-dose ranibizumab as primary treatment of posterior type I retinopathy of prematurity.
    Ells AL; Wesolosky JD; Ingram AD; Mitchell PC; Platt AS
    Can J Ophthalmol; 2017 Oct; 52(5):468-474. PubMed ID: 28985806
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Short-term retinal detachment risk after treatment of type 1 retinopathy of prematurity with laser photocoagulation versus intravitreal bevacizumab.
    Barry GP; Tauber KA; Fisher M; Greenberg S; Zobal-Ratner J; Binenbaum G
    J AAPOS; 2019 Oct; 23(5):260.e1-260.e4. PubMed ID: 31513902
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Monotherapy: Timing and Risk Factors.
    Lyu J; Zhang Q; Chen CL; Xu Y; Ji XD; Li JK; Huang QJ; Zhao PQ
    Invest Ophthalmol Vis Sci; 2017 Mar; 58(3):1719-1725. PubMed ID: 28324112
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Morphological outcome and indication for laser following intravitreal bevacizumab monotherapy for posterior retinopathy of prematurity.
    Sindal MD; Nagesha CK; Yadav D; Fazal R
    Lasers Med Sci; 2022 Jul; 37(5):2501-2508. PubMed ID: 35106690
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Regression Rates Following the Treatment of Aggressive Posterior Retinopathy of Prematurity with Bevacizumab Versus Laser: 8-Year Retrospective Analysis.
    Nicoară SD; Ștefănuţ AC; Nascutzy C; Zaharie GC; Toader LE; Drugan TC
    Med Sci Monit; 2016 Apr; 22():1192-209. PubMed ID: 27062023
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment.
    Süren E; Özkaya D; Çetinkaya E; Kalaycı M; Yiğit K; Kücük MF; Erol MK
    Int Ophthalmol; 2022 Jun; 42(6):1905-1913. PubMed ID: 35094229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.